The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.

Hematopoietic Stem Cell Transplantation Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy Lymphocyte Transfusion Lymphocytes Protein Kinase Inhibitors / therapeutic use Recurrence Retrospective Studies
Chronic myeloid leukemia Donor lymphocyte infusion Hematopoietic cell transplantation Tyrosine kinase inhibitor

Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
06 2020
Historique:
received: 04 12 2019
revised: 15 01 2020
accepted: 04 02 2020
pubmed: 18 2 2020
medline: 24 6 2021
entrez: 17 2 2020
Statut: ppublish

Résumé

Treatment for relapse of chronic myeloid leukemia (CML) following hematopoietic cell transplantation (HCT) includes tyrosine kinase inhibitors (TKIs) with or without donor lymphocyte infusions (DLIs), but the most effective treatment strategy is unknown. This study was performed through the Center for International Blood and Marrow Transplant Research (CIBMTR) database. We retrospectively reviewed all patients reported to the CIBMTR registry from 2002 to 2014 who underwent HCT for CML and were alive 30 days postrelapse. A total of 215 HCT recipients relapsed and were analyzed in the following groups: (1) TKI alone (n = 128), (2) TKI with DLI (n = 48), and (3) DLI without TKI (n = 39). In multivariate analysis, disease status prior to HCT had a significant effect on overall survival (OS). Patients who received a DLI alone compared with a TKI with a DLI had inferior survival (hazard ratio, 2.28; 95% confidence interval, 1.23 to 4.24; P= .009). Those who received a TKI alone had similar survival compared with those who received a TKI with a DLI (P = .81). These data support that despite use of TKIs pretransplantation, TKI salvage therapy continues to provide significant survival following relapse in patients with CML following HCT. These data do not suggest that adding a DLI to a TKI adds an improvement in OS.

Identifiants

DOI: 10.1016/j.bbmt.2020.02.006 PMID: 32062061 PMC: PMC7367282
pubmed: 32062061
pii: S1083-8791(20)30090-2
doi: 10.1016/j.bbmt.2020.02.006
pmc: PMC7367282
mid: NIHMS1589931
pii:
doi:

Substances chimiques

Protein Kinase Inhibitors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1137-1143

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI126612
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL140314
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231141
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131731
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126589
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA152108
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129472
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

J Clin Oncol. 1997 Feb;15(2):433-44
pubmed: 9053463
J Clin Oncol. 2005 Oct 20;23(30):7583-93
pubmed: 16234522
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Bone Marrow Transplant. 2005 Dec;36(11):1009-15
pubmed: 16205732
J Transplant. 2009;2009:357093
pubmed: 20107580
Cancer Control. 2002 Mar-Apr;9(2):123-37
pubmed: 11965233
Leuk Lymphoma. 2015 Jan;56(1):128-34
pubmed: 24712979
Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6
pubmed: 25797175
N Engl J Med. 2010 Jun 17;362(24):2251-9
pubmed: 20525993
Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58
pubmed: 18541193
Leukemia. 2007 May;21(5):943-8
pubmed: 17361226
Blood. 2002 Sep 1;100(5):1590-5
pubmed: 12176876
Curr Hematol Malig Rep. 2015 Jun;10(2):158-66
pubmed: 25700679
Blood. 2000 Oct 15;96(8):2712-6
pubmed: 11023502
Biol Blood Marrow Transplant. 2010 May;16(5):639-46
pubmed: 20005967
Cancer. 2017 Aug 1;123(15):2875-2880
pubmed: 28387926
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):87-92
pubmed: 24252361
Clin Cancer Res. 2004 Aug 1;10(15):5065-71
pubmed: 15297408
Leukemia. 2003 Sep;17(9):1707-12
pubmed: 12970768
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Bone Marrow Transplant. 2007 Feb;39(3):189-91
pubmed: 17211436
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Blood. 1995 Sep 1;86(5):2041-50
pubmed: 7655033
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):177-184
pubmed: 30504307
Blood. 2011 Oct 27;118(17):4567-76
pubmed: 21865346
N Engl J Med. 2010 Jun 17;362(24):2260-70
pubmed: 20525995

Auteurs

Sarah Schmidt (S)

Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, Oklahoma. Electronic address: Sarah-Schmidt@ouhsc.edu.

Ying Liu (Y)

CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.

Zhen-Huan Hu (ZH)

CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Kirsten M Williams (KM)

Children's Research Institute, Children's National Health Systems, Washington, DC.

Hillard M Lazarus (HM)

Case Western Reserve University, Cleveland, Ohio.

Ravi Vij (R)

Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri.

Mohamed A Kharfan-Dabaja (MA)

Divsion of Hematology-Oncology, Blood and Marrow Transplant Program, Mayo Clinic, Jacksonville, Florida.

Guillermo Ortí (G)

Hematology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Peter H Wiernik (PH)

Our Lady of Mercy Medical Center, Bronx, New York.

Daniel Weisdorf (D)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota.

Rammurti T Kamble (RT)

Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.

Roger Herzig (R)

Markey Cancer Center, University of Kentucky, Lexington, Kentucky.

Baldeep Wirk (B)

Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.

Jan Cerny (J)

Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.

Ulrike Bacher (U)

Department of Hematology, Inselspital, Bern University Hospital, Switzerland.

Naeem A Chaudhri (NA)

Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Sunita Nathan (S)

Rush University Medical Center, Chicago, Illinois.

Nosha Farhadfar (N)

Division of Hematology/Oncology, Department of Medicine, University Florida College of Medicine, Gainesville, Florida.

Mahmoud Aljurf (M)

Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Usama Gergis (U)

Hematologic Malignancies and Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.

Jeffrey Szer (J)

Clinical Hematology at Peter MacCalluma Cancer Centre and The Royal Melbourne Hospital, Victoria, Australia.

Sachiko Seo (S)

Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.

Jack W Hsu (JW)

Rush University Medical Center, Chicago, Illinois.

Richard F Olsson (RF)

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.

Dipnarine Maharaj (D)

South Florida Bone Marrow Stem Cell Transplant Institute, Boynton Beach, Florida.

Biju George (B)

Christian Medical College, Vellore, India.

Gerhard C Hildebrandt (GC)

Markey Cancer Center, University of Kentucky, Lexington, Kentucky.

Vaibhav Agrawal (V)

Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.

Taiga Nishihori (T)

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Hisham Abdel-Azim (H)

Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.

Edwin Alyea (E)

Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Uday Popat (U)

MD Anderson Cancer Center, Houston, Texas.

Ronald Sobecks (R)

Cleveland Clinic Foundation, Cleveland, Ohio.

Bart L Scott (BL)

Fred Hutchinson Cancer Research Center, Seattle, Washington.

Jennifer Holter Chakrabarty (J)

Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, Oklahoma.

Wael Saber (W)

CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › The Role of Donor Lymphocyte Infusion (DLI) in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Role of Donor Lymphocyte Infusion (DLI) in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie myéloïde chronique BCR-ABL positive › The Role of Donor Lymphocyte Infusion (DLI) in...
questionsmedicales.fr › Thérapeutique › Biothérapie › Transfusion sanguine › Transfusion de composants du sang › Transfusion de leucocytes › Transfusion de lymphocytes › The Role of Donor Lymphocyte Infusion (DLI) in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › The Role of Donor Lymphocyte Infusion (DLI) in...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › The Role of Donor Lymphocyte Infusion (DLI) in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › The Role of Donor Lymphocyte Infusion (DLI) in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › The Role of Donor Lymphocyte Infusion (DLI) in...